Friday, December 13, 2019

December 13, 2019 at 07:48PM IMLYGIC (talimogene laherparepvec)

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2rzG7I8

No comments:

Post a Comment